Related references
Note: Only part of the references are listed.HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Yanjun Hou et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
Carla Rios-Luci et al.
CANCER RESEARCH (2017)
Gene expression profiling of breast cancer in Lebanese women
Joelle Makoukji et al.
SCIENTIFIC REPORTS (2016)
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab
Arvind M. Shinde et al.
BREAST (2015)
A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer
Seungyoon Nam et al.
CANCER LETTERS (2015)
mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer
Silvia von der Heyde et al.
PLOS ONE (2015)
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis
Antonis Valachis et al.
BREAST (2011)
Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
Helena R. Chang
CANCER (2010)
Beyond HER2 and Trastuzumab: Heterogeneity, Systems Biology, and Cancer Origin Research May Guide the Future for Personalized Treatment of Very Early but Aggressive Breast Cancer
Dimitrios H. Roukos
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists
Da Wei Huang et al.
GENOME BIOLOGY (2007)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:: implications for tumor immune escape
I Algarra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
International expert panel on the use of primary (Preoperative) systemic treatment of operable breast cancer: Review and recommendations
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
